- Home
- ELBM vs CMMB Comparison
ELBM vs CMMB Comparison
Compare ELBM & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- CMMB
- Stock Information
- Founded
- ELBM 2011
- CMMB 2004
- Country
- ELBM Canada
- CMMB Israel
- Employees
- ELBM N/A
- CMMB N/A
- Industry
- ELBM Industrial Machinery/Components
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- ELBM Miscellaneous
- CMMB Health Care
- Exchange
- ELBM Nasdaq
- CMMB Nasdaq
- Market Cap
- ELBM 29.6M
- CMMB 27.0M
- IPO Year
- ELBM N/A
- CMMB N/A
- Fundamental
- Price
- ELBM $0.50
- CMMB $1.60
- Analyst Decision
- ELBM Strong Buy
- CMMB Strong Buy
- Analyst Count
- ELBM 1
- CMMB 3
- Target Price
- ELBM $1.40
- CMMB $7.33
- AVG Volume (30 Days)
- ELBM 55.1K
- CMMB 119.1K
- Earning Date
- ELBM 11-15-2024
- CMMB 11-14-2024
- Dividend Yield
- ELBM N/A
- CMMB N/A
- EPS Growth
- ELBM N/A
- CMMB N/A
- EPS
- ELBM N/A
- CMMB N/A
- Revenue
- ELBM N/A
- CMMB N/A
- Revenue This Year
- ELBM N/A
- CMMB N/A
- Revenue Next Year
- ELBM $1,630.56
- CMMB N/A
- P/E Ratio
- ELBM N/A
- CMMB N/A
- Revenue Growth
- ELBM N/A
- CMMB N/A
- 52 Week Low
- ELBM $0.26
- CMMB $0.42
- 52 Week High
- ELBM $0.75
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- ELBM 41.64
- CMMB 52.53
- Support Level
- ELBM $0.46
- CMMB $1.54
- Resistance Level
- ELBM $0.58
- CMMB $1.73
- Average True Range (ATR)
- ELBM 0.04
- CMMB 0.16
- MACD
- ELBM -0.00
- CMMB 0.01
- Stochastic Oscillator
- ELBM 35.04
- CMMB 45.45
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.